-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2172 Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged over 70 Years with Myelofibrosis

Program: Oral and Poster Abstracts
Session: 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster I
Hematology Disease Topics & Pathways:
Bone Marrow Failure Syndromes, Diseases, Treatment Considerations, Biological therapies, Transplantation (Allogeneic and Autologous)
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Moazzam Shahzad, MD1,2, Muhammad Kashif Amin, MD2,3,4*, Ben Ponvilawan, MD2,3*, Hana Qasim2*, Matthew McGuirk2,3*, Sibgha Gull Chaudhary, MD3,4*, Iqra Anwar, MBBS2,3*, Abat Khan, MD2,3*, Abdulraheem Yacoub, MD2,5*, Anurag K. Singh, MD2,3,4, Mehdi Hamadani, MD6, Joseph P. McGuirk, DO2,3,4 and Muhammad Umair Mushtaq3,4,7

1Department of Oncological Sciences, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL
2Mikael Rayaan Foundation Global Health Consortium, Kansas City, KS
3Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
4US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS
5University of Kansas Medical Center, Westwood, KS
6Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
7MRF, Kansas City

Background: Myelofibrosis (MF) is a chronic myeloproliferative neoplasm that typically presents in the elderly population. Allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only curative option for MF. However, allo-HCT carries significant morbidity in older patients. Our study aims to determine the clinical factors that can help predict allo-HCT outcomes in patients over 70 years.

Methods: We analyzed the publicly available Center for International Blood and Marrow Transplant Research (CIBMTR) P-5646 dataset (Murthy et al.) containing 872 patients with chronic-phase MF who received allo-HCT from 2008 to 2019. Outcomes of interest included overall survival (OS), disease-free survival (DFS), graft-versus-host disease-free relapse-free survival (GRFS), acute graft-versus-host disease (aGVHD), chronic GVHD (cGVHD), relapse rate, and non-relapse mortality (NRM) in the subgroup with age 70 years or above. OS, DFS, and GRFS were censored at 24 months per the dataset. Hazard ratios (HR) with 95% confidence intervals (CI) were determined using univariate and multivariate Cox regression analyses were performed. Statistical analysis was conducted using R version 4.3.2, with statistical significance defined as p <0.05.

Results: We identified 51 patients from the dataset and included them in our analysis. The median age at HCT was 71.8 (range 70.1-77.9) years, of which 32 (62.7%) were male and 47 (92.2%) were non-Hispanic Caucasian. The median time from diagnosis to transplant was 27.3 months. Splenomegaly before HCT was present in 54% of patients. Ruxolitinib was used before HCT in 69% of patients. MF Dynamic International Prognostic Scoring System (DIPSS)-Plus risk categories were intermediate-1 (4%), intermediate-2 (63%), and high-risk (33%). The type of donor used was matched unrelated donors (MUD, 82%), matched related donors (MRD, 12%), and mismatched unrelated donors (MMUD, 6%) patients, respectively. Most (94.1%) of grafts were from peripheral blood stem cells. The 24-month OS, DFS, and GRFS rates were 58.8%, 30.6%, and 12.2%, respectively. A trend for inferior OS (HR 4.46, 95% CI 1.00– 19.97, p=0.05) and inferior DFS (HR 3.89, 95% CI 0.88–17.27, p=0.07) was found in Hispanic patients, which was a significant predictor after multivariate adjustments (HR for OS 13.67, 95% CI 1.71–108.50, p=0.01 and HR for DFS 14.38, 95% CI 2.17–95.40, p=0.006, respectively). The use of MMUD was associated with significantly inferior OS (HR 7.14, 95% CI 1.31–38.98, p=0.02), DFS (HR 6.26, 95% CI 1.33–29.54, p=0.02) and GRFS (HR 4.70, 95% CI 1.06–20.83, p=0.04) compared to HLA-identical sibling donors, and only impact on OS remained significant after multivariate adjustments (HR 10.29, 95% CI 1.25–84.99, p=0.03). No association between clinical factors and other outcomes was found.

Conclusion: Outcomes after allogeneic HCT are acceptable in elderly patients with MF, with a 2-year survival rate of 59%. Patients of Hispanic ethnicity and the use of MMUD were associated with inferior outcomes. Careful patient selection and use of matched donors are suggested.

Keywords: Hematopoietic cell transplantation, Allogeneic transplantation, Donor type, Myelofibrosis, Elderly, Survival outcome, Clinical outcome

Disclosures: Yacoub: Acceleron: Consultancy; AbbVie: Consultancy; Gilead: Consultancy; PharmaEssentia: Consultancy; Pfizer: Consultancy; Novartis: Consultancy; Apellis: Consultancy; Notable Labs: Consultancy; BMS: Consultancy; Incyte: Consultancy; CTI Pharma: Consultancy; Servier: Consultancy; Celgene: Consultancy. Hamadani: Spectrum Pharmaceuticals: Research Funding; ADC Therapeutics: Consultancy, Research Funding, Speakers Bureau; Forte Biosciences: Consultancy; Kite Pharma: Consultancy, Speakers Bureau; Astellas Pharma: Research Funding; Sanofi Genzyme: Speakers Bureau; AstraZeneca: Speakers Bureau; DMC, Inc: Speakers Bureau; BeiGene: Speakers Bureau; Omeros: Consultancy; Byondis: Consultancy; Genentech: Speakers Bureau; AbbVie: Consultancy; BMS: Consultancy; Autolus: Consultancy; CRISPR: Speakers Bureau; Takeda: Research Funding; Myeloid Therapeutics: Speakers Bureau; Caribou: Consultancy; Allovir: Consultancy; CRISPR: Consultancy; Genmab: Consultancy. McGuirk: CRISPR therapeutics: Consultancy; Legend biotech: Consultancy; Sana technologies: Consultancy; Autolus: Consultancy; Novartis: Consultancy; BMS: Consultancy; Caribou bio: Consultancy; Kite: Consultancy; Envision: Consultancy; Allo Vir: Consultancy; NEKTAR therapeutics: Consultancy. Mushtaq: Iovance Biotherapeutics: Research Funding.

*signifies non-member of ASH